おすすめの製品
由来生物
synthetic
グレード
pharmaceutical primary standard
認証
EP Reference Standard
APIファミリー
famotidine
形状
solid
包装
pkg of 110 mg
メーカー／製品名
EDQM
保管条件
protect from light
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
輸送温度
ambient
保管温度
2-8°C
SMILES記法
N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1
InChI
1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
InChI Key
XUFQPHANEAPEMJ-UHFFFAOYSA-N
遺伝子情報
human ... HRH2(3274)
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
Famotidine is a hydrophilic, cationic, histamine H2 receptor antagonist drug that effectively inhibits gastric acid secretion in humans.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
アプリケーション
This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.
生物化学的／生理学的作用
H2ヒスタミンレセプタ-のアンタゴニストであり、抗潰瘍薬です。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
関連製品
製品番号
詳細
価格
保管分類コード
11 - Combustible Solids
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
最新バージョンのいずれかを選択してください：
H Echizen et al.
Clinical pharmacokinetics, 21(3), 178-194 (1991-09-01)
Famotidine is a potent histamine H2-receptor antagonist widely used in the treatment and prevention of peptic ulcer disease. After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and
M C Martinez
The Annals of pharmacotherapy, 33(6), 742-747 (1999-07-20)
To evaluate the use and potential benefit of famotidine in the management of schizophrenia. Clinical literature accessed through MEDLINE (February 1998-October 1998). Key search terms included famotidine, schizophrenia, and histamine. Schizophrenia is a complicated disorder associated with high morbidity if
A N Chremos
Journal of clinical gastroenterology, 9 Suppl 2, 7-12 (1987-01-01)
Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect in humans is inhibition of gastric acid secretion. Dose-related suppression of basal and stimulated (meal, pentagastrin) gastric acid output has been shown with oral doses of 5-40 mg. The
C W Howden et al.
Clinical therapeutics, 18(1), 36-54 (1996-01-01)
Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients
[Famotidine--a new histamine H2 receptor blockader].
P Ia Grigor'ev et al.
Klinicheskaia meditsina, 69(4), 23-28 (1991-04-01)
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）